Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Free Radic Biol Med. 2014 Mar 24;71:208–220. doi: 10.1016/j.freeradbiomed.2014.03.018

Fig. 5.

Fig. 5

Effect of the Alda-1 activator Alda-1 on cardiomyocyte O2− production and mechanical properties in young (4–5 month-old) or old (26–28 month-old) mice in the absence or presence of activators of AMPK and Sirt1 (AICAR, resveratrol and SRT1720). Mice were treated with Alda-1 (20 mg/kg, i.p., twice per week) in the presence or absence of the AMPK activator AICAR (0.5 mg/g, i.p. twice per week), the mixed AMPK/Sirt1 activator resveratrol (5 mg/kg, i.p., twice per week) or the Sirt1 activator SRT1720 (100 mg/kg, gavage, twice per week) for 4 weeks prior to assessment of cardiac O2− production and mechanical function. A: O2− production; B: Peak shortening (normalized to cell length); C: Maximal velocity of shortening (+ dL/dt); D: Maximal velocity of relengthening (− dL/dt); E: Time-to-PS (TPS); and F: Time-to-90% relengthening (TR90). Mean ± SEM, n = 8 independent isolations (panel A) or 72 cells (panels B–F) per group, *p < 0.05 vs. Young group, # p < 0.05 vs. Old group. † p < 0.05 vs. Old-Alda-1 group.